Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on September 3, 2013. The report discloses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate event and does not contain financial statements.
Material Changes
On September 3, 2013, Alfred Akirov resigned as a member of the Board of Directors, effective immediately. The resignation was attributed to increasing demands from his other business interests outside the country and other time constraints.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific departure of the director.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Akirov's resignation.
- Confirm whether the resignation triggers any changes to committee assignments or quorum requirements.
- Review subsequent filings for any appointment of a replacement director.